Global research trends and hotspots of Helicobacter pylori eradication based on clinical trial registration platforms: A cross-sectional analysis - 03/12/23
, Pei-Yuan Li a, b, ⁎ Highlights |
• | H. pylori infection attracted much attention worldwide, and its popularity will continue to increase. |
• | Asia, especially China, Iran, South Korea and Japan paid the most attention on H. pylori eradication. |
• | The most studied eradication regimens varied in different regions at different time stages. |
• | BQT, P-CABs-based therapy, probiotics, and HDDT attracted the most attention in recent years. |
Abstract |
Background |
This study aimed to obtain an overview of clinical trials on Helicobacter pylori (H. pylori) eradication and analyze the global trends and hotspots in this field.
Methods |
We collected the data from clinical trials focused on H. pylori eradication in the primary clinical trial registries from 2000 to 2022 in the world. Then we analyzed the research trends and hotspots in H. pylori eradication regimens in different regions at different periods.
Results |
A total of 780 clinical trials were included, which were mainly conducted in Asia (682), followed by Europe (59), Africa (20), North America (16), South America (7), Oceania (2). The most active countries were China (343), Iran (140), South Korea (63), and Japan (73). “Bismuth-containing quadruple therapy (BQT)” was the most studied regimen (159, 20.38 %). Additionally, clinical trials focused on potassium-competitive acid blockers (P-CABs)-based therapy, probiotics, and high-dose dual therapy (HDDT) were constantly increasing. BQT received the most attention in China (26.53 %) and Iran (22.14 %), while it was tailored therapy in South Korea (23.29 %). P-CABs-based therapy was the main reseach hotspot in Japan (61.90 %).
Conclusion |
How to eradicate H. pylori infection has been a heated research topic. BQT, P-CABs-based therapy, probiotics, and HDDT attracted the most attention in recent years.
Il testo completo di questo articolo è disponibile in PDF.Keywords : Helicobacter pylori, Research trend, Eradication regimens, Clinical trial
Mappa
Vol 47 - N° 10
Articolo 102233- Dicembre 2023 Ritorno al numero
Articolo precedente
- Effect on lipid profile and clinical outcomes of obeticholic acid for the treatment of primary biliary cholangitis and metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis
- Hyejung Jang, Nayoung Han, Christine E. Staatz, Jae-Hwan Kwak, In-hwan Baek
- LINC01579–204 involved in the development of Hirschsprung's disease maybe by regulating the expression of miR-203a-3p and NEFL
- Dingjiang Qin, Wenyi Yang, Xiaochun Zhu, Chunfang Tang, Like Yuan, Lu Xu, Song Tian, Rong Huang, Dongyun Zhang, Shangjie Xiao
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?